[AP] - Drug developer GTx Inc. posted a deeper second-quarter loss Monday, saying its revenue plunged and it recorded a charge tied to a late-stage clinical trial that failed to find its drug toremifene prevents prostate cancer.
[Business Wire] - MEMPHIS, Tenn.----GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009.
[Business Wire] - MEMPHIS, Tenn.----GTx, Inc. today announced that it will host a conference call and webcast to discuss the Company's second quarter 2010 results on Monday, August 9 at 9:00 a.m. Eastern.
[Indie Research] - The small-cap biopharmaceutical and medical devices segments often lure traders with big intraday swings, and the potential for massive gains in the event of an FDA approval, major partnership, or outright buyout.
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the secondquarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million 2010 08 09 07:00
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to discuss the Company's second quarter 2010 results on Monday, August 9 at 9:00 a.m. Eastern. The call and 2010 07 26 07:00
GTx, Inc. (Nasdaq: GTXI) announced that Ostarine? (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective 2010 06 21 07:00
GTx, Inc. (Nasdaq: GTXI) announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in 2010 06 08 07:00
I am pleased to introduce a new weekly service called Insider Weekends that highlights buying and selling of stock by company insiders. Numerous academic studies have found that insiders as a whole tend to outperform the general market. A 2007 study by Alan D. Jagolinzer, an assistant professor at the Stanford University Graduate School of Business, found that even insiders that were enrolled in “automated” 10b5-1 plans where they periodically sell certain amounts of stocks according to the plan, ...
The U.S. Food and Drug Administration is investigating reports of complications with dozens of recalled children's medications made by Johnson & Johnson (JNJ), including 30 deaths, but so far no direct link has been found, according to a Congressional staff report, Reuters reported. “At this time, FDA is not aware of any child being harmed by taking one of the recalled products,” according to the report. “FDA is still investigating some of these adverse events to determine if the events were related to a child taking one of the recalled medicines.” A Congressional hearing...
GTx’s (GTXI) main shot at redemption for its lead pipeline candidate, toremifene (acapodene), failed to deliver with the release Tuesday night of phase III data that showed no significant reduction in the risk of developing prostate cancer in patients with a premalignant lesion.
Having already failed to convince the FDA of the drug’s effectiveness and safety in preventing bone fractures in men undergoing prostate cancer treatment (FDA words not sticks and stones hurt GTx’s bone drug, November 2, 2009), the results from this three-year, 1,600 patient study could have provided a...
Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA news/decisions or clinical trial results that are expected within the next three months. A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events approximately 3-6 months ahead of the expected catalyst date, and sell into the expected upward momentum in both stock price and trading volume.
New Jersey biotech CorMedix priced its initial public offering during an otherwise quiet week for life sciences financings and deals. Its stock will trade on the NYSE Amex under the symbol "CRMD.U." The company is focused on developing and commercializing therapeutics for the treatment of cardiac and renal dysfunction. CorMedix is the fourth biotech company to go public in 2010 in a market that has been lukewarm to high-risk biotech companies. Ironwood Pharmaceuticals, Anthera, and Aveo Pharmaceuticals all priced below their expected range.
On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we provided a positive outlook for biotechnology, citing the sector’s defensive characteristics, favorable technical aspects, and improving fundamentals, such as the number of new product approvals, products in clinical trials and the brisk pace of industry consolidation and licensing transactions.
Gilead Sciences (GILD) said darusentan, the company’s experimental drug to treat resistant hypertension, failed in a late-stage clinical trial. Darusentan, an endothelin receptor antagonist, did not achieve its two primary endpoints in a comparison to a placebo. “We are disappointed that darusentan did not achieve its primary endpoints in this study,” said Norbert Bischofberger, Gilead’s executive vice president of research and development and chief scientific officer. “As a result, we think it would be challenging to define an expedient path forward. We would likely be required to initiate another phase III study and would rather...
Northrop unloads TASC. Northrop Grumman (NOC) agreed to sell its TASC consulting unit to a pair of private-equity firms - KKR and General Atlantic - for $1.65B. TASC unit provides engineering and consulting services to the U.S. military and state governments. Northrop said it expects the sale to generate net cash proceeds of $1.1B, which it will use to repurchase shares. The deal is the latest in a recent uptick in LBO acquisitions which have...
Below is a list of the healthcare sector companies that made news in the healthcare sector on Monday, November 2, 2009. This list feature is meant to help investors keep tabs on the sector without having to scour through all the press releases.
Bristol-Myers Squibb (NYSE:BMY) announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir.
Although Dow Jones is at 10,252.48 with a gain of 2.37%.NASDAQ is at 2,171.20 with a gain of 2.70%. GTx, Inc. (Public, NASDAQ:GTXI) shares are at $3.01 with a loss of -0.14 (-4.44%) at Real-time ...
By Chip Brian When GTx (NASDAQ:GTXI) reported earnings 11 days ago on August 09, 2010, analysts, on average, expected the company to report a loss of $0.28 on sales of $2 million. The company ...
NEW YORK (Market Intellisearch) -- GTXI options saw interesting put activity today. A total of 38 put and 49 call contracts were traded raising a three month record high put volume alert. Today's ...
Dow Jones is at 10,323.05 with a gain of 0.03%.NASDAQ is at 2,182.48 with a fall of -0.36%. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares are at $4.47 with a gain of +0.46 (11.42%) at Real ...
A total of 0 puts traded in today's trading session. On the calls side, 21 contracts were exchanged. Today's traded Put/Call ratio is 0.75. There were 1.33 calls traded for each put contract. The ...
By Chip Brian Below are the top five companies in the Biotechnology industry as ranked by gross margin. Gross Margin tells you how many of your sales dollars are profit. If efficiency is improved ...
Below are the top 10 Biotechnology stocks with highest Return on Equity (ROE) ratio for the last 12 months. ROE shows a company's efficiency in making profits from shareholders' equity. It is ...
By Luke Ruther on Tuesday, August 10th, 2010 GTx, Inc. (NADAQ:GTXI), Keryx Biopharmaceuticals (NASDAQ:KERX), and Medivation, Inc. (Nasdaq: MDVN) are a few companies focused on bringing new ...
Gtx Inc. has a market cap of $122.74 million; its shares were traded at around $3.37 with a P/E ratio of 12.96 and P/S ratio of 8.33. Gtx Inc. had an annual average earning growth of 6.7% over the ...
By Chip Brian Analysts, on average, expect GTx (NASDAQ:GTXI) to report a loss of $0.28 per share on sales of $2 million on August 09, 2010. For the full year, analysts expect the company to post ...
Stock News 
